The Phase III IMpassion130 study, investigating TECENTRIQ® plus Abraxane® for triple-negative breast cancer, has met its progression-free survival endpoint.
Browsing: Phase III
ESMO WCGI: Trifluridine and tipiracil show promise as metastatic gastric cancer treatment in Phase III trial
Clinical data demonstrates improvement in metastatic gastric cancer patient overall survival in comparison with the placebo.
Phase III IM power150 study has demonstrated that atezolizumab and bevacizumab plus carboplatin and paclitaxel helped individuals with advanced lung cancer live longer compared to avastin plus carboplatin and paclitaxel.
FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer
Discover details of the first randomized, multicenter Phase III study to compare the safety and efficacy of mirvetuximab soravtansine vs investigator’s choice of chemotherapy in women with folate receptor-α-positive, platinum-resistant epithelial ovarian, primary peritoneal or fallopian tube cancer.
Data from the CheckMate-227 trial has demonstrated that its cancer drug combination has reached its primary endpoint of progression-free survival.
Researchers have demonstrated that treatment with sodium thiosulfate significantly reduced cisplatin-induced hearing difficulties in children and adolescents with cancer.
Niraparib, a highly selective PARP inhibitor, has been demonstrated to significantly improve progression-free survival in patients with platinum-sensitive recurrent ovarian cancer, regardless of BRCA-mutation status.
ESMO16: Atezolizumab significantly improves lung cancer survival vs standard chemotherapy in Phase III trial
A collaborative study presented at ESMO16 suggests that the PD-L1 inhibitor atezolizumab reduces the risk of death in patients with advanced non-small-cell lung cancer.
Results from the ongoing VIVIANE study find the human papillomavirus 16/18 vaccine is effective in protecting women over the age of 25 years against infection.
Phase III data indicate that regorafenib increases survival rates in patients with hepatocellular carcinoma, highlighting potential as a second-line therapy.